- Home
- SGRY vs ADPT Comparison
SGRY vs ADPT Comparison
Compare SGRY & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGRY | ADPT |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SGRY | ADPT |
|---|---|---|
| Price | $15.48 | $17.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $27.00 | $16.60 |
| AVG Volume (30 Days) | 1.3M | ★ 2.0M |
| Earning Date | 03-02-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,288,100,000.00 | $252,754,000.00 |
| Revenue This Year | $7.76 | $50.86 |
| Revenue Next Year | $8.16 | $0.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 10.14 | ★ 42.57 |
| 52 Week Low | $14.94 | $6.26 |
| 52 Week High | $26.16 | $20.76 |
Technical Indicators
Market Signals| Indicator | SGRY | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 54.85 |
| Support Level | $15.29 | $16.55 |
| Resistance Level | $16.44 | $18.14 |
| Average True Range (ATR) | 0.54 | 0.91 |
| MACD | 0.06 | 0.12 |
| Stochastic Oscillator | 23.23 | 68.50 |
Price Performance
Historical ComparisonAbout SGRY Surgery Partners Inc.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).